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Abstract
Background
There are few data on the prevalence of obesity and its influence on achieving blood glu-
cose, blood pressure, and blood lipid (3B) goals in Chinese type 2 diabetes outpatients.
Methods
Patient demographic data, anthropometric measurements, medications, and blood glucose
and lipid profiles of 24,512 type 2 diabetes patients from a large, geographically diverse
study (CCMR-3B) were analyzed. Using cut-points for body mass index (BMI) and waist cir-
cumference (WC) recommended by the Working Group on Obesity in China, overweight
and obesity were defined as BMIs of 24–27.9kg/m2 and28.0kg/m2. Central obesity was
defined as a waist circumference80cm in women and85cm in men. The 3B therapeutic
goals were HbA1c<7.0%, BP<140/90mmHg and LDL-C<2.6mmol/L.
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Results
Overall, 43.0% of type 2 diabetes patients were overweight and 16.7% were obese; 13.3%
of overweight and and10.1% of obese patients achieved all the 3B target goals. Overweight
or obese patients were less likely to achieve 3B goals than those with normal BMIs. More
than a half the overweight or obese patients (69.6%) were centrally obese. Patients with
abdominal obesity were less likely to achieve cardiometabolic targets than those without
abdominal obesity. In multivariate logistic regression analysis, female, higher BMI and waist
circumference, smoking, drinking, sedentary lifestyle, and longer diabetes duration were
significantly correlated with failure to achieve 3B control goals.
Conclusions
Obesity is highly prevalent and associated with poor 3B control in Chinese type 2 diabetes
patients. In clinical practice, more attention and resources should focus on weight loss for
such patients.
Introduction
The global prevalence of diabetes is rapidly increasing, and in China, the estimated prevalence
of type 2 diabetes in adults rose from 2.5% in 1994 to 9.7% in 2007–2008 [1, 2]. There is strong
evidence from epidemiological studies showing that obese diabetes patients are at increased
risk of cardiometabolic diseases including hyperglycemia, hypertension, and dyslipidemia [3–
6]. A meta-analysis of five longitudinal cohort studies demonstrated that overweight or obese
diabetes patients had a twofold greater relative risk of mortality than normal-weight patients
[7]. However, currently no studies have directly compared the rates of achieving therapeutic
goals for control of hyperglycemia, hypertension, and dyslipidemia in normal weight and
obese patients with diabetes who had been receiving medical care in hospital setting.
Cardiovascular events contribute to morbidity and mortality from diabetes, but control of
cardiometabolic risk factors among diabetes patients is reported to be poor [8]. Identification
of the factors that contribute to poor control would help to reduce morbidity and mortality in
these patients. Overweight and obesity are characterized by excessive body fat accumulation
that impairs both physical and psychosocial health. General obesity, i.e., overall body fat, is
usually estimated by the body mass index (BMI), and waist circumference (WC), which mea-
sures abdominal fat, is the easiest way to assess central obesity. A survey of 233 type 2 diabetes
patients, found that control of hyperglycemia, hypertension, and dyslipidemia was poor in
65.7%, 51.9%, and 97.1% of the subjects respectively, and that 60.1% of them were either over-
weight or obese [8]. Study supports the combined use of general and central obesity, as mea-
sured by BMI andWC, to assess risk of cardiovascular diseases in patients with diabetes and
metabolic disorders [9].
Current type 2 diabetes treatment guidelines recommend multifactorial intervention,
including both lifestyle modification and pharmacologic treatment [10,11]. However, even
with multifactorial interventions, it is not known if diabetes patients with different BMIs have
similar success in achieving recommended target goals for control of hyperglycemia, hyperten-
sion, and dyslipidemia in a real-life setting. We evaluated a population of overweight and obese
patients from the Nationwide Assessment of Cardiovascular Risk Factors: Blood Glucose,
Blood Pressure, and Blood Lipid (3B) study, a large, cross-sectional investigation of Chinese
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patients with type 2 diabetes [12]. We aimed to assess the achievement of 3B goals in this popu-
lation and to compare the proportions of patients with different BMIs who achieved the target
therapeutic goals set by the parent study. The influence of lifestyle on achieving the 3B targeted
goals was assessed.
Materials and Methods
Study design and participants
The 3B study was conducted from August 2010 to March 2011 in endocrinology, cardiology,
nephrology, and internal medicine clinics in 104 hospitals across all major geographic regions
in China (registered in clinicaltrials.gov, NCT01128205). The study design and population
have been described previously [12]. Briefly, it was a purely observational study, as only avail-
able data were documented, and patient treatment or assessment was not changed by the
study. Endocrinology, cardiology, nephrology, and internal medicine specialists conducted the
study. Consecutive outpatients were eligible for inclusion if they were 18 years of age or older
and were diagnosed with type 2 diabetes at least 6 months prior to study screening. The study
protocol was approved by the Ethics Committees of Peking University People’s Hospital,
China–Japan Friendship Hospital, The Third Affiliated Hospital of Sun Yat-sen University,
Huashan Hospital Fudan University, Shanghai Changzhen Hospital, Jiangsu Province Hospi-
tal, and The Second Affiliated Hospital of Dalian Medical University. All patients provided
written informed consent to participate. Of 25,454 eligible patients, 610 with a BMI<18.5 kg/
m2, and 23 with missing data, including BMI, hemoglobin A1c (HbA1c), total cholesterol
(TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol
(HDL-C), or triglycerides (TG), were excluded. An additional 309 participants with extreme
values (i.e., below the 0.1 percentile or above the 99.9 percentile) of age, BMI, duration of dia-
betes, LDL-C, TC, HDL-C, TG, and HbA1c were excluded. The remaining 24,512 patients
(11,543 men and 12,969 women) were included in this study.
Data collection
Patient data were collected from medical charts and clinical examinations conducted at one
outpatient visit. Information on health behavior (i.e., smoking status, alcohol consumption,
and exercise intensity), current medications, and personal history of hypertension and major
cardiovascular diseases were obtained by self-reporting during a face-to-face interview. Physi-
cal examination included anthropometry and blood pressure measurements; height and weight
were measured with patients standing with bare feet and light clothing on a mechanical bal-
ance. Fasting serum glucose, TC, LDL-C, HDL-C, and TG were measured at each study site
with an automated analyzer. An HbA1c concentration known to have been obtained during
the 3 months prior to the enrollment visit, or obtained at enrollment, was recorded.
Definitions of variables
Smoking was defined as consuming an average of at least one cigarette daily for at least 1 year.
Drinking was defined as consuming an average at least 50 g of alcohol daily for at least 1 year.
A sedentary lifestyle was defined as not participating in regular physical activities.
BMI was calculated as weight in kilograms divided by the square of height in meters (kg/
m2). As recommended by the Working Group on Obesity in China, normal weight was defined
as a BMI of 18.5–23.9 kg/m2, overweight as a BMI of 24.0–27.9, and obesity as a BMI of 28.0
kg/m2 or higher [13–15]. A normal WC was defined as<80cm in women and<85 cm in men;
WCs80cm in women and85cm in men indicated central obesity [13].
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Each patient was evaluated for attainment of 3B study therapeutic control goals. According
to the China Guidelines for Type 2 Diabetes (2013) and the American Diabetes Association
recommendations (2015) [16,17], attainment of the glycemic goal was defined as an HbA1c
<7%, the blood pressure (BP) goal was a systolic blood pressure (SBP)<140mmHg and a dia-
stolic blood pressure (DBP)<90mmHg regardless of a history of hypertension or current anti-
hypertensive treatment. The LDL-C goal was<2.6mmol/l regardless of a history of
dyslipidemia or current anti-hyperlipidemia treatment.
Statistical analysis
Statistical analysis was performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
Quantitative variables were expressed as means±standard deviation (SD) or medians and per-
centiles (25th percentile, 75th percentile). Categorical variables were reported as numbers and
percentages. Between-group differences of continuous variables were tested for significance
using one-way analysis of variance (ANOVA), and the chi-square or Fisher’s exact test were
used for categorical data. Logistic regression analysis was used to determine the independent
association between attainment of 3B therapeutic goals and the variables of age, gender, smok-
ing status, alcohol consumption, sedentary lifestyle, BMI, WC, diabetes duration, and diabetes
complications. Backward elimination (= 0.05) was performed. The results were expressed as
odds ratios (ORs) with 95% confidence intervals (CIs). Statistical significance was accepted as a
two-sided test with an alpha level of 0.05.
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of the 24,512 patients with type 2 diabetes were
stratified by BMI and WC and are shown in Table 1. The prevalence of overweight was 43.0%
(n = 10,548), and 16.7% (n = 4098) of the patients were obese; 11,543 (47.1%) were men and
12,969 (52.9%) were women. The mean age of normal-weight diabetes patients was 63.5
±11.6years, overweight patients were 62.2±11.7years of age, and obese patients were 60.8
±12.4years of age (P<0.001). Obese patients had a shorter diabetes duration than normal-
weight patients, but were more likely to have comorbidities (hypertension or hypertension
with dyslipidemia). Alcohol consumption and sedentary lifestyle were more common in obese
than in normal-weight patients. A greater percentage of overweight and obese patients had dia-
betes complications, including cardiovascular diseases, cerebrovascular disease, and nephropa-
thy, compared with normal-weight patients (all P<0.05).
Of the 9546 overweight patients with a BMI24kg/m2 (excluding 5,100 patients with miss-
ing WC data), 6642 (69.6%) were centrally obese; and of those, 69.5% were men. A significantly
larger percentage of patients with central obesity had comorbidities compared with those who
had a normal WC (76.5% vs. 71.8%, P<0.001). Centrally obese patients were also more likely
to be smokers or alcohol drinkers (P<0.001).
Medication regimens
The numbers and percentages of patients receiving pharmaceutical treatment for diabetes,
hypertension, and dyslipidemia are shown in Table 2. The most frequently reported oral antidi-
abetic agents were metformin (38.6%), followed by sulfonylureas (28.9%) and -glucosidase
inhibitors (26.6%). Use of antihypertensive, lipid lowering and oral antidiabetic agents was
most frequent in obese patients. More than half of the obese patients (52.3%) were taking anti-
hypertensive agents, and more than a quarter (27.9%) were taking blood-lipid lowering agents,
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compared with 37.6% and 19.8% of normal-weight patients, respectively (P<0.001). More cen-
trally obese patients than patients with a normal WC were taking antihypertensive and oral
antidiabetic agents (P<0.001). Interestingly, insulin treatment did not vary among patients
with different BMI.
Control of blood glucose, blood pressure and blood lipids
The 3B profiles and goal-attainment rates of the study patients are shown in Table 3. Over-
weight and obese patients had higher SBP, DBP, and fasting serum glucose, HbA1c, TC,
LDL-C and TG, but lower HDL-C levels than normal-weight patients (P<0.05). Centrally
obese patients had higher HbA1c and TG levels, but lower HDL-C levels than did patients with
a normal WC (P<0.05).
A total of 44.9% of the patients reached the recommended glycemic control target (HbA1c
<7%); 40.3% achieved the BP target (<140/90mmHg), and 42.5% reached the lipid control tar-
get (LDL-C<2.6mmol/L). All 3B target goals (i.e., control of HbA1c, BP, and LDL-C) were
Table 1. Demographic and clinical characteristics of diabetes patients stratified by BMI andWC.
Total
(n = 24,512)
BMI (kg/m2) BMI 24kg/m2
<24
(n = 9866)
24–27.9
(n = 10,548)
28
(n = 4098)
P Normal WC
(n = 2904)
Central obesity
(n = 6642)
P
Age, years (mean±SD) 62.5±11.8 63.5±11.6 62.2±11.7 60.8±12.4 <0.001 62.0±11.8 60.6±12.1 <0.001
<45 1697 (6.9) 576 (5.8) 717 (6.8) 404 (9.9) <0.001 202 (7.0) 631 (9.5) <0.001
45–54 4408 (18.0) 1615 (16.4) 1968 (18.7) 825 (20.1) 572 (19.7) 1386 (20.9)
55–64 7323 (29.9) 2856 (28.9) 3263 (30.9) 1204 (29.4) 888 (30.6) 2032 (30.6)
65 11084 (45.2) 4819 (48.8) 4600 (43.6) 1665 (40.6) 1242 (42.8) 2593 (39.0)
Male 11543 (47.1) 4524 (45.9) 5291 (50.2) 1728 (42.2) <0.001 1345 (46.3) 4614 (69.5) <0.001
Diabetes duration, years,
median (25th, 75th percentile)
6.2 (2.7, 11.3) 6.7 (2.7,
12.0)
6.0 (2.7,11.0) 5.9 (2.5,
10.9)
<0.001 6.0 (2.6, 11.0) 5.7 (2.4, 10.8) 0.001
<1 2210 (9.0) 897 (9.1) 950 (9.0) 363 (8.9) <0.001 265 (9.1) 653 (9.8) 0.002
1–4 8135 (33.2) 3101 (31.4) 3578 (33.9) 1456 (35.5) 967 (33.3) 2399 (36.12)
5–9 5878 (24.0) 2289 (23.2) 2579 (24.5) 1010 (24.6) 704 (24.2) 1622 (24.42)
10 8289 (33.8) 3579 (36.3) 3441 (32.6) 1269 (31.0) 968 (33.3) 1968 (29.6)
Comorbidities* 17756 (72.4) 6447 (65.3) 7931 (75.2) 3378 (82.4) <0.001 2084 (71.8) 5079 (76.5) <0.001
Hypertension 7367 (30.1) 2926 (29.7) 3150 (29.9) 1291 (31.5) 866 (29.8) 1942 (29.2)
Dyslipidemia 3018 (12.3) 1156 (11.7) 1404 (13.3) 458 (11.2) 351 (12.1) 973 (14.7)
Hypertension and
Dyslipidemia
7371 (30.1) 2365 (24.0) 3377 (32.0) 1629 (39.8) 867 (29.9) 2164 (32.6)
Smoking 4052 (16.5) 1433 (14.5) 1921 (18.2) 698 (17.0) <0.001 471 (16.2) 1669 (25.1) <0.001
Alcohol consumption 1959 (8.0) 607 (6.2) 958 (9.1) 394 (9.6) <0.001 227 (7.8) 876 (13.2) <0.001
Sedentary lifestyle 8824 (36.0) 3403 (34.5) 3692 (35.0) 1729 (42.2) <0.001 1031 (35.5) 2313 (34.8) 0.522
Diabetes complications
Cardiovascular diseases 3653 (14.9) 1266 (12.8) 1663 (15.8) 724 (17.7) <0.001 458 (15.8) 1004 (15.1) 0.413
Cerebrovascular disease 2469 (10.1) 981 (9.9) 1061 (10.1) 427 (10.4) 0.694 245 (8.4) 653 (9.8) 0.032
Peripheral vascular diseases 370 (1.5) 161 (1.6) 132 (1.3) 77 (1.9) 0.009 31 (1.1) 85 (1.3) 0.384
Nephropathy 3525 (14.4) 1271 (12.9) 1540 (14.6) 714 (17.4) <0.001 377 (13.0) 1021 (15.4) 0.002
Retinopathy 4018 (16.4) 1698 (17.2) 1645 (15.6) 675 (16.5) 0.008 409 (14.1) 891 (13.4) 0.380
Neuropathy 3702 (15.1) 1486 (15.1) 1545 (14.6) 671 (16.4) 0.032 387 (13.3) 933 (14.1) 0.348
Data are expressed as n (%) unless otherwise indicated.
* Comorbidities included hypertension only, dyslipidemia only, and both conditions.
doi:10.1371/journal.pone.0144179.t001
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achieved by 14.3% of the study participants. A total of 48.6% of normal-weight patients
achieved HbA1c control, 47.2% achieved BP control, and 17.2% achieved all the 3B target goals
compared with 38.7%, 30.0% and 10.1% of obese patients, respectively (P<0.001). A similar
trend was seen in centrally obese patients, suggesting that patients who had an abnormal BMI
and an abnormal WC were at increased risk of failure to achieve target therapeutic goals.
Risk factors that influence the 3B control
Logistic regression analysis showed (Table 4) that higher BMI (OR = 1.26; 95%CI, 1.15–1.38
for BMI = 24–27.9kg/m2 and OR = 1.62; 95%CI, 1.37–1.93 for BMI28 kg/m2), higher WC
Table 2. Medication regimens of diabetes patients stratified by BMI andWC.
BMI (kg/m2) BMI 24kg/m2
Total
(n = 24,512)
<24
(n = 9866)
24–27.9
(n = 10,548)
28
(n = 4098)
P Normal WC
(n = 2904)
Central obesity
(n = 6642)
P
Antihypertensive
agents
10577 (43.2) 3711 (37.6) 4722 (44.8) 2144 (52.3) <0.001 1244 (42.8) 2965 (44.6) <0.001
Lipid lowering agents 5776 (23.6) 1954 (19.8) 2679 (25.4) 1143 (27.9) <0.001 715 (24.6) 1727 (26.0) 0.473
Oral anti-diabetic
agents
17992 (73.4) 7140 (72.4) 7753 (73.5) 3099 (75.6) <0.001 2019 (69.5) 4919 (74.1) <0.001
Metformin 9460 (38.6) 3314 (33.6) 4216 (40.0) 1930 (47.1) <0.001 1064 (36.6) 2774 (41.8) 0.131
α-glucosidase
inhibitors
6527 (26.6) 2664 (27.0) 2774 (26.3) 1089 (26.6) 0.031 696 (24.0) 1735 (261.) 0.424
Sulfonylureas 7075 (28.9) 3038 (30.8) 3016 (28.6) 1021 (24.9) <0.001 752 (25.9) 1816 (27.3) 0.664
Thiazolidinediones 1820 (7.4) 677 (6.9) 782 (7.4) 361 (8.8) 0.289 159 (5.5) 530 (8.0) 0.098
Insulin 8688 (35.4) 3414 (34.6) 3788 (35.9) 1486 (36.3) 0.072 1077 (37.1) 2334 (35.1) 0.068
Data are expressed as n (%)
doi:10.1371/journal.pone.0144179.t002
Table 3. 3B profiles and goal attainment rates of diabetes patients stratified by BMI andWC.
BMI (kg/m2) BMI 24 kg/m2
Total
(n = 24,512)
<24
(n = 9866)
24–27.9
(n = 10,548)
28
(n = 4098)
P Normal WC
(n = 2904)
Central obesity
(n = 6642)
P
SBP (mmHg) 133.1±15.7 131.2±15.4 133.8±15.5 135.9±16.1 <0.001 133.4±15.5 133.5±15.4 0.797
DBP (mmHg) 78.9±8.9 77.3±8.5 79.4±8.8 81.4±9.5 <0.001 79.7±9.0 80.0±9.0 0.088
FPG (mmol/L) 8.4±3.4 8.3±3.5 8.4±3.3 8.6±3.3 <0.001 8.4±3.5 8.4±3.2 0.849
HbA1c (%) 7.6±2.0 7.5±2.1 7.6±1.9 7.8±1.9 <0.001 7.5±2.0 7.7±1.9 0.003
TC (mmol/L) 4.97±1.21 4.95±1.22 4.97±1.20 5.01±1.21 0.015 5.01±1.24 4.92±1.18 0.092
LDL-C (mmol/L) 2.84±0.91 2.82±0.90 2.95±0.91 2.86±0.92 0.014 2.84±0.92 2.83±0.90 0.570
HDL-C (mmol/L) 1.30±0.43 1.35±0.44 1.27±0.42 1.26±0.44 <0.001 1.29±0.45 1.24±0.41 <0.001
TG (mmol/L) 1.98±1.65 1.76±1.42 2.09±1.75 2.25±1.80 <0.001 2.03±1.49 2.17±1.93 <0.001
HbA1c <7.0% 11,000 (44.9) 4793 (48.6) 4623 (43.8) 1584 (38.7) <0.001 1341 (46.2) 2834 (42.7) 0.001
BP <140/90
mmHg
9885 (40.3) 4655 (47.2) 4000 (37.9) 1230 (30.0) <0.001 1930 (66.5) 4313 (64.9) 0.150
LDL-C <2.6
mmol/L
10,426 (42.5) 4287 (43.5) 4427 (42.0) 1712 (41.8) 0.057 1254 (43.2) 2858 (43.0) 0.890
3B at goal 3512 (14.3) 1696 (17.2) 1401 (13.3) 415 (10.1) <0.001 426 (14.7) 853 (12.8) 0.016
FPG, fasting plasma glucose. *3B goal was BP<140/90mmHg, LDL-C<2.6mmol/L, and HbA1c<7.0%. Data are shown as means±SD or n (%).
doi:10.1371/journal.pone.0144179.t003
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(OR = 1.01; 95%CI, 1.01–1.02), smoking (OR = 1.38; 95%CI, 1.22–1.57), drinking (OR = 1.31;
95%CI, 1.10–1.55), and longer diabetic duration (OR = 1.69; 95%CI, 1.46–1.95 for 5–9 years
and OR = 1.45; 95% CI, 1.25–1.68 for10 years) made it less likely to achieve 3B control goals.
Male patients (OR = 0.78; 95%CI, 0.71–0.86) and frequent exercisers (OR = 0.85; 95%CI, 0.78–
0.93) were more likely to achieve all 3B control targets.
Discussion
Although the attainment of integrated glycemic, blood pressure and lipid goal is recommended
by the current diabetes treatment guidelines, a smaller percentage of obese or overweight diabe-
tes patients were able to achieve 3B goals compared with normal-weight patients. Furthermore,
we observed that central obesity was significantly correlated with failure to achieve the 3B goal.
To our knowledge, the present analysis is a first study to systematically assess the effect of obe-
sity on 3B control in a large, geographically diverse sample of patients with type 2 diabetes.
Given the upward trajectory in prevalence of obesity in diabetes, our findings clearly illustrate
the importance of weight control for improving the 3B control rate and reducing the disease
burden.
The health consequences of diabetes are compounded by overweight and obesity. In this
study, 43.0% of diabetes patients were overweight and 16.7% were obese. In fact, we overesti-
mated overweight and obesity based on the Chinese-specific BMI cutoffs of 24 and 28kg/m2
relative to the WHO criteria of 25 and 30kg/m2. Therefore, we recalculated the prevalence of
Table 4. Factors associated with failure to achieve 3B goals by logistic regression analysis.
Variables BP <140/90mmHg LDL-C <2.6mmol/L HbA1c <7.0% 3B at goal
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Age (years), vs. <45years
45–54 1.63 (1.39, 1.91) <0.001 1.02 (0.90, 1.16) 0.727 0.76 (0.66, 0.87) <0.001 1.05 (0.88, 1.25) 0.611
55–64 1.89 (1.62, 2.20) <0.001 1.15 (1.02, 1.31) 0.022 0.56 (0.50, 0.64) <0.001 1.03 (0.87, 1.23) 0.699
65 2.29 (1.96, 2.66) <0.001 0.94 (0.83, 1.07) 0.340 0.48 (0.43, 0.55) <0.001 0.85 (0.72, 1.01) 0.060
Gender (male vs. female) 0.98 (0.91, 1.06) 0.616 0.67 (0.62, 0.72) <0.001 0.97 (0.90, 1.04) 0.350 0.78 (0.71, 0.86) <0.001
Smoking (yes vs. no) 1.00 (0.91, 1.10) 0.991 1.12 (1.02, 1.22) 0.012 1.41 (1.29, 1.54) <0.001 1.38 (1.22, 1.57) <0.001
Drinking (yes vs. no) 1.18 (1.05, 1.33) 0.006 1.11 (0.99, 1.24) 0.067 1.15 (1.03, 1.29) 0.016 1.31 (1.10, 1.55) 0.002
Exercise (yes vs. no) 0.87 (0.82, 0.94) <0.001 0.99 (0.93, 1.04) 0.653 0.77 (0.72, 0.82) <0.001 0.85 (0.78, 0.93) <0.001
BMI (kg/m2) vs. <24kg/m2
24–27.9 1.30 (1.21, 1.40) <0.001 1.04 (0.97, 1.11) 0.298 1.11 (1.04, 1.19) 0.002 1.26 (1.15, 1.38) <0.001
28 1.66 (1.48, 1.87) <0.001 1.03 (0.92, 1.16) 0.567 1.25 (1.11, 1.4) <0.001 1.62 (1.37, 1.93) <0.001
Abnormal WC vs. normal WC 1.01 (1.00, 1.01) <0.001 1.01 (1.00, 1.01) 0.002 1.01 (1.01, 1.02) <0.001 1.01 (1.01, 1.02) <0.001
Diabetes duration (years), vs. <1year
1–4 1.05 (0.93, 1.18) 0.466 1.00 (0.89, 1.11) 0.931 0.95 (0.85, 1.06) 0.383 1.06 (0.92, 1.21) 0.415
5–9 1.25 (1.11, 1.42) <0.001 0.99 (0.88, 1.10) 0.813 1.99 (1.77, 2.22) <0.001 1.69 (1.46, 1.95) <0.001
10 1.11 (0.98, 1.26) 0.106 1.02 (0.91, 1.15) 0.682 1.44 (1.28, 1.61) <0.001 1.45 (1.25, 1.68) <0.001
Diabetes complications (yes vs. no)
Cardiovascular 1.18 (1.08, 1.29) <0.001 0.70(0.64, 0.77) <0.001 0.93 (0.85, 1.01) 0.093 0.82 (0.73, 0.92) <0.001
Cerebrovascular 1.37 (1.23, 1.52) <0.001 0.93 (0.84, 1.02) 0.133 1.05 (0.95, 1.17) 0.350 1.15 (1.00, 1.34) 0.057
Peripheral 1.47 (1.14, 1.89) 0.003 0.96 (0.75, 1.23) 0.737 1.20 (0.92, 1.56) 0.178 1.53 (0.99, 2.37) 0.055
Nephropathy 1.68 (1.54, 1.84) <0.001 0.96 (0.88, 1.04) 0.312 1.05 (0.96, 1.15) 0.258 1.40 (1.22, 1.60) <0.001
Retinopathy 1.18 (1.08, 1.29) <0.001 1.05 (0.96, 1.15) 0.258 0.96 (0.88, 1.05) 0.385 1.07 (0.94, 1.20) 0.305
Neuropathy 1.13 (1.03, 1.24) 0.009 1.06 (0.97 1.15) 0.211 1.47 (1.34, 1.61) <0.001 1.29 (1.13, 1.47) <0.001
doi:10.1371/journal.pone.0144179.t004
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overweight and obesity in this Chinese population using the WHO criteria, which gave preva-
lences of 38.77% (9503/24 512) for overweight and 7.14% (1750/24 512) for obesity in our
study population. These rates are considerably lower than the percentages reported in a survey
conducted in the United States in 1999–2002 [18]. In that survey, the combined prevalence of
overweight and obesity (BMI25kg/m2) was 85.2%, and the prevalence of obesity (BMI
30kg/m2) was 54.8%. A systematic literature review found a high variability in the prevalence
of obesity in type 2 diabetes patients living in different countries [19]. Given the differences of
ethnicities, country specified obesity criteria (e.g., BMI, WC, and waist/hip ratio) and obesity
thresholds should be adapt for the country.
Hyperglycemia, hypertension, and dyslipidemia occur frequently in type 2 diabetes patients
[19,20]. Iwahashi et al. reported that after oral glucose loading, insulin levels were higher in
obese than in non-obese type 2 diabetes patients [21]. Obese (BMI30kg/m2) type 2 diabetes
patients treated at a clinic in the UK had higher blood pressure and triglyceride levels than
nonobese patients, and that total cholesterol and glycemic control were worse in obese than
nonobese male patients [22]. Similarly, our study found that overweight or obesity was associ-
ated with increased likelihood of comorbid hypertension and/or dyslipidemia. Overweight and
obese patients also had higher SBP, DBP, fasting serum glucose, HbA1c, TC, LDL-C, and TG,
but lower HDL-C levels than normal-weight patients. We also found that comorbidities
occurred more often in overweight patients with central obesity than in those with a normal
WC. Overall, these findings are in line with the Look AHEAD (Action for Health in Diabetes)
study, a long-term trial of lifestyle intervention for weight loss that reported weight loss
improved glycemic control, blood pressure, and lipid profiles in overweight type 2 diabetes
patients [23].
In this study, the most frequently used oral antidiabetic agents were metformin (38.6%), sul-
fonylureas (28.9%), and α-glucosidase inhibitors (26.6%). A clinical trial conducted in Chinese
patients with newly diagnosed type 2 diabetes reported no differences in the efficacy of metfor-
min monotherapy to reduce HbA1c and LDL-C levels in normal weight, overweight, or obese
patients after 16 weeks of treatment [24]. Another observational study reported similar reduc-
tions of glycaemia in patients with different BMIs after insulin detemir was added to treatment
regimens that included oral glucose lowering drugs [25]. In this study, obese patients had
higher average levels of TC, TG, and HbA1c, than other patients, but antihypertensive, lipid
lowering and oral antidiabetic agents were used more frequently in obese than in other
patients. This suggests that obese patients might require more complex pharmacological ther-
apy to modify their cardiovascular risk factors.
Overall, only 14.3% of the enrolled patients achieved all 3B target goals. The proportion of
3B-controled patients decreased in overweight and obese patients, with only 10.1% of obese
patients achieving all three therapeutic targets. Our findings confirm the negative impact of
obesity on achieving 3B treatment goals, and that the negative effects were not offset by phar-
macotherapy, emphasizing the known benefit of weight loss in diabetes patients [26,27]. The
occurrence of hypertension, diabetes, and hyperlipidemia along with obesity has been referred
to as a cardiometabolic risk factor cluster (CMRFC) [28]. More than 80% of the diabetes
patients in this study had one or more concomitant cardiovascular risk factor, which made the
choice of a treatment regimen complex and presented a significant challenge to effective
achievement of 3B targets. The logistic regression analysis found that a BMI24kg/m2 and an
abnormal WC predicted failure to achieve the 3B therapeutic goals. Interestingly, our logistic
regression results indicated that BMI seemed to be a stronger predictor than waist circumfer-
ence. Determining this with certainty, however, will require long-term follow-up and further
investigation.
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Lifestyle can influence achievement of therapeutic goals for control of hyperglycemia,
hypertension, and dyslipidemia in diabetic patients. In this study, alcohol consumption and a
sedentary lifestyle were reported by more obese than normal weight patients. Frequent exercise
might be of benefit in achieving 3B control. Qin et al. proposed that obesity and physical activ-
ity have an additive impact, and that prevention of either obesity or physical inactivity effec-
tively reduces the risks of diabetes and its comorbid cardiometabolic diseases [29]. Physical
activity may increase insulin sensitivity, glucose disposal, and oxidation of free fatty acids [29].
Moreover, the benefits of physical activity may extend beyond weight loss alone to include
reduction of systemic and vascular inflammation [30]. Thus, 150 min/week of regular physical
activity has been recommended as an intervention in diabetes treatment [10]. However, some
studies have found that exercise had no measurable effect on glucose regulation in obese indi-
viduals without concomitant weight loss, and that the beneficial effect of exercise on metabolic
complications seems only achievable when accompanied by weight loss [29]. In this study,
smoking and drinking appeared to be independent risk factors for the failure to attain 3B goals.
Therefore, overweight or obese patients with type 2 diabetes should be encouraged to adopt
preventive lifestyle interventions, including frequent exercise and restriction of smoking and
drinking habits.
This analysis of a large, geographically diverse population of type 2 diabetes patients adds to
our knowledge of the negative effects of overweight or obesity on control of cardiometabolic
risk in patients with type 2 diabetes. The main study limitation was its cross-sectional design,
which made it difficult to confirm a causal relationship between obesity and failure to achieve
treatment goals. This needs to be further explored in subsequent follow-up analyses of the 3B
Study. Also, because the WC data was incomplete in nearly half the patients, the difference in
3B control achieved by centrally obese and non-centrally obese patients might be subject to
selection bias. In addition, we did not include data on adherence to antidiabetic medication in
the analysis. Finally, because dietary data were not available in the 3B Study, the relationships
between diet and obesity or diet and 3B control could not be evaluated.
Conclusions
Obesity was associated with poor control of blood glucose, blood pressure and blood lipids.
The risk of cardiovascular complications thus remained increased in obese patients even
though they were receiving more complex pharmacotherapy regimens than normal weight
patients were. More attention and resources should be focused on encouraging and achieving
weight loss and increased physical activity in patients with type 2 diabetes.
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